eSENSE Break™ uses next-generation sequencing to map RNA fragmentation sites at single-nucleotide resolution across linear mRNA, self-amplifying RNA, and circular RNA therapeutics. For linear mRNA, eSENSE Break pinpoints fragmentation hotspots across the sequence, giving positional data to refine designs and manufacturing processes. For circular RNA, eSENSE Break maps nicking sites that drive linearization, exposing vulnerable positions on the molecule for sequence redesign or process optimiza

NAPA, Calif., June 1, 2026 /PRNewswire/ -- The Doctors Company, the nation's largest physician-owned medical malpractice insurer, today released "Oncology Claims: June Malpractice Risk Review," the newest edition in a monthly series of specialty-focused analyses designed to support patient safety and clinical risk management. Each month in 2026, The Doctors Company will explore malpractice risk trends in a different medical specialty, offering evidence-based insights drawn from real claims data

Advancing practical, responsible AI innovation in highly regulated industries NEW YORK, June 1, 2026 /PRNewswire/ -- Kedrion Biopharma and InstaLILY are hosting the Rare Connections: Healthcare AI Innovation Summit on June 3 as part of NY Tech Week. The invitation-only, half-day forum will bring together thought leaders across pharma, technology, investment, and research to explore how organizations are operationalizing artificial intelligence responsibly and at scale. Continue Reading Rare Con

Expanding enterprise-ready precision medication infrastructure positioned for large-scale integration across healthcare technology, pharmacy, and payer markets. TWINSBURG, Ohio, June 1, 2026 /PRNewswire/ -- The U.S. Patent and Trademark Office has issued U.S. Patent No. 12,640,242 on May 26, 2026, granting federal intellectual property protection to Xact Laboratories. This patent validates Xact Laboratories' proprietary technology, reinforcing the company's commitment to advancing personalized

LUND, Sweden, June 1, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in June 2025. The decision extends Lilly's exclusive, global rights to Camurus' FluidCrystal® technology for the development and commercialization of long acting cardiometabolic drug medicines to an additional compound class. The agreement comprises up to

LUND, Sweden, June 1, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in June 2025. The decision extends Lilly's exclusive, global rights to Camurus' FluidCrystal® technology for the development and commercialization of long acting cardiometabolic drug medicines to an additional compound class. The agreement comprises up to

Applications open June 1 for UCB's Hidradenitis Suppurativa Scholarship™ Program Informed by patient insights, the initiative builds on UCB's network of scholarship programs in myasthenia gravis and epilepsy ATLANTA, June 1, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the launch of the inaugural UCB Hidradenitis Suppurativa Scholarship™ Program, designed to support adults age 18 and older living with hidradenitis suppurativa (HS), and their immediate family memb

Committee Recommends Expanding Sample Size After Interim Analysis Places Study in Protocol-Defined Promising Zone SAN DIEGO, June 1, 2026 /PRNewswire/ -- Ansun Biopharma, Inc., a clinical-stage biopharmaceutical company, today announced that its independent Data Monitoring Committee (DMC) has issued a positive recommendation following a prespecified interim efficacy and safety review of the Company's Phase 3 clinical trial (DAS181-3-01). DAS181 is being evaluated for the treatment of parainfluen

Darovasertib combination resulted in a statistically significant and clinically meaningful improvement in median PFS vs. investigator's choice of therapy (ICT) – 6.9 months vs. 3.1 months, HR: 0.42, 58% reduction in risk of disease progression Significantly improved ORR (37.1% vs 5.8%) and DCR (73.3% vs. 31.1%) by BICR vs. ICT, where ~77% were treated with ipilimumab + nivolumab OS not yet mature but early trend favoring the darovasertib combination; targeting to provide the next update as part

Company announcement No. 20 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 22, 2026) Copenhagen, Denmark, June 1, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 22 (May 26-29, 2026). The Program is carried out in accordance with Article 5 of Regulation (EU)